๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shanghai
Clinical trial register · China

Clinical Trials in Shanghai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Fudan University454 Ruijin Hospital276 Shanghai Zhongshan Hospital163 RenJi Hospital135 Children's Hospital of Fudan University84
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Shanghai

3827 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Evaluation of PWI Assisted by Marshall Ethanolization in Ablation of Persistent Atrial Fibrillation
NCT06363604Atrial Fibrillation
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
260
Shanghai
2023-12-01
Recruiting
Conditioning Regimen of Melphalan-busulfan and Fludarabine: a Randomized Study of Different Dose of Melphalan
NCT06829472Toxicities, Survivorship
DrugMelphalan
Shanghai Jiao Tong University School of Medicine
Phase 3
120
Shanghai
2023-12-01
Not yet open
The Efficacy of Heparin-boned Viabahn Endoprosthesis and Paclitaxel-coated Balloons for Complex Femoropopliteal Lesions
NCT06124755Peripheral Arterial Disease
RenJi Hospital
Not applicable
60
Shanghai
2023-12-01
Not yet open
Evaluation of the Safety, Tolerability and Efficacy of Gene Therapy Drug for Late Onset Pompe Disease (LOPD)
NCT06178432Pompe Disease (Late-onset)
Huashan Hospital
Phase EARLY_PHASE1
6
Shanghai
2023-12
Not yet open
Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial
NCT06178211Esophageal Squamous Cell Carcinoma
Shanghai Chest Hospital
Phase 2
36
Shanghai
2023-12
Not yet open
PET Imaging of 68Ga-NOTA-H006 in Malignancy
NCT06162988Tumor, Solid
YiHui Guan
Not applicable
15
Shanghai
2023-12
Recruiting
Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma
NCT06876688CNS Lymphoma
Ruijin Hospital
Phase 2
30
Beijing, Guangzhou, Henan, Shanghai, Wuhan
2023-11-30
Active, closed
A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy
NCT05988073Multifocal Motor Neuropathy
argenx
Observational
413
Changsha, Nanchang, Shanghai
2023-11-29
By invitation
Potential Biomarkers and Pathogenic Mechanism for Reflux Aspiration-induced Lung Injury.
NCT06164639ARDS, Human, Aspiration Pneumonia
Shanghai Zhongshan Hospital
Observational
28
Shanghai
2023-11-28
Recruiting
A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC)
NCT06108492Intermediate and High-risk Non-muscle Invasive Bladder Cancer
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1
170
Shanghai
2023-11-28
Recruiting
DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer
NCT06178159Breast Cancer
DrugsPertuzumab·Disitamab Vedotin·Tislelizumab
RemeGen Co., Ltd.
Phase 2
40
Shanghai
2023-11-28
Recruiting
Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid Tumors
NCT06132828Solid Tumor
DrugDR30206
Zhejiang Doer Biologics Co., Ltd.
Phase 1
216
Shanghai
2023-11-27
Recruiting
The Role of B7-H4 in Tumor Vaccine
NCT06156150Glioma
DrugTumor vaccine
Huashan Hospital
Observational
160
Shanghai
2023-11-26
Recruiting
Prognosis of Patients With Upper Tract Urothelial Carcinoma Receiving Kidney-sparing Therapy
NCT06204406Upper Tract Urothelial Carcinoma Receiving Kidney-sparing Therapy
RenJi Hospital
Observational
106
Shanghai
2023-11-23
Recruiting
A Clinical Trial of Parkinson's Disease Treatment by HiPSCs Derived Dopaminergic Neural Precursor Cells
NCT06145711Parkinson's Disease
Shanghai East Hospital
Not applicable
3
Shanghai
2023-11-23
Recruiting
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
NCT06131840Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma
DrugsLeucovorin·Oxaliplatin·Bevacizumab
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
914
Guangzhou, Jinan, Shanghai
2023-11-20
Recruiting
A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer
NCT06158919Gastric Cancer/Adenocarcinoma of Esophagogastric Junction
Fudan University
Not applicable
58
Shanghai
2023-11-20
Active, closed
A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
NCT06126640HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
DrugsTrastuzumab emtansine·Trastuzumab Rezetecan
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
1,615
Shanghai, Tianjin
2023-11-20
Recruiting
Safety, Tolerability, and Pharmacokinetic Characteristics of SSS11 in Patients With Gout and Hyperuricemia
NCT06629376Gout, Hyperuricemia
Shenyang Sunshine Pharmaceutical Co., LTD.
Phase 1
60
Shanghai
2023-11-20
Recruiting
Robot-assisted vs VATS for Thymoma
NCT06029621Thymoma
Shanghai Pulmonary Hospital, Shanghai, China
Not applicable
304
Shanghai, Zhejiang
2023-11-20
By invitation
Gut Microbiota and Metabolic Development in Early Childhood: A 3-Year Follow-Up Study
NCT07762729Gut Microbiota, Early Child Development
Children's Hospital of Fudan University
Observational
1,000
Yiyang, Nantong, Shanghai, Baoji, Quzhou
2023-11-16
Recruiting
Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma
NCT06091124Neuroendocrine Carcinoma of the Bladder, Bladder Cancer
DrugsCDDP·Etoposide·Adebrelimab·Cisplatin
RenJi Hospital
Phase 2
22
Nanjing, Xi'an, Shanghai, Chengdu, Tianjin
2023-11-16
Recruiting
A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma
NCT06136351Lymphoma, Mantle-Cell
DrugsZanubrutinib·Rituximab
Ruijin Hospital
Phase 2
23
Shanghai
2023-11-15
Active, closed
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
NCT05870579Breast Cancer
Drugs[177Lu]Lu-NeoB·[68Ga]Ga-NeoB·Ribociclib·Fulvestrant
Novartis Pharmaceuticals
Phase 1
28
Shanghai
2023-11-13
Recruiting
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)
NCT05319353Cytomegalovirus (CMV)
DrugMaribavir
Takeda
Phase 3
80
Beijing, Guangzhou, Shenzhen, Shanghai, Tianjin
2023-11-13
Recruiting
Fractional Flow Reserve Guided Immediate Versus Staged Complete Myocardial Revascularization in Patients With ST-segment Elevation Myocardial Infarction With Multivessel Disease (Future Study)
NCT05967663ST Elevation Myocardial Infarction
RenJi Hospital
Not applicable
840
Shanghai
2023-11-11
Active, closed
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
NCT05925803Systemic Sclerosis, Scleroderma
AstraZeneca
Phase 3
314
Beijing, Guangzhou, Hangzhou, Lanzhou, Shanghai, Tianjin
2023-11-08
Recruiting
Safety and Efficacy of OCN19-overexpressed Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Refractory Type 2 Diabetes Mellitus
NCT06727721Diabetes, Type 2 Diabetes
Lu jin ๏ผŒMD
Phase 2
10
Shanghai
2023-11-06
Recruiting
Neoadjuvant Treatment For Locally Advanced Thymic Cancer
NCT06019468Thymic Carcinoma
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
25
Shanghai
2023-11-04
Recruiting
Oral Prednisone in Treating LCH of Bone in Childhood and Adolescence
NCT06078969Langerhans Cell Histiocytosis of Bone
Shanghai Changzheng Hospital
Phase 2
118
Shanghai
2023-11-04
Active, closed
Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL
NCT06093841Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma, Mediastinal B-Cell Diffuse Large Cell Lymphoma
DrugsRelmacabtagene Autoleucel·Fludarabine·Cyclophosphamide
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 2
46
Guangzhou, Zhengzhou, Changsha, Suzhou, Jinan, Shanghai, Tianjin, Hangzhou
2023-11-03
Recruiting
The Treatment of Ocular Adnexal Extranodal Marginal Zone B-cell Lymphoma by Orelabrutinib and Radiotherapy
NCT06503276Extranodal Marginal Zone B-cell Lymphoma
DrugOrelabrutinib
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2
50
Shanghai
2023-11-01
Recruiting
Cohort in Qianwan New District, Ningbo
NCT06387875Cardiovascular Diseases, Stroke, Non-Communicable Chronic Diseases
RenJi Hospital
Observational
30,000
Shanghai
2023-11-01
Recruiting
Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer
NCT06017284Pancreatic Cancer Stage IV, Chemotherapy-induced Nausea and Vomiting
Fudan University
Phase 3
100
Shanghai
2023-11-01
Active, closed
PET-CT Predicting Lymph Nodes Metastasis
NCT05970913Non Small Cell Lung Cancer, Lymph Node Metastasis, Positron Emission Tomography
Fudan University
Observational
280
Shanghai
2023-11-01
Recruiting
HRYZ-T101 Injection for HPV18 Positive Solid Tumor
NCT05952947Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Carcinoma of Vagina, Carcinoma of Penis
DrugsFludarabine·Cyclophosphamide
HRYZ Biotech Co.
Phase 1
32
Shanghai
2023-11-01
Recruiting
Surveillance for Multifocal GGNs
NCT06097910Lung Ground-glass Opacities, Active Surveillance
Fudan University
Observational
370
Shanghai
2023-11-01
Recruiting
Study of Adrenocorticotropic Hormone on Children With Frequent Relapse or Steroid-dependent Nephrotic Syndrome: a Prospective, Multicenter, Randomized๏ผŒOpen-label Clinical Trial.
NCT06079788Nephrotic Syndrome in Children
Mao Jianhua
Phase 3
140
Wuhan, Nanjing, Kunming, Hangzhou, Ningbo, Wenzhou, Beijing, Shanghai
2023-11-01
Recruiting
Short-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer
NCT05891561Breast Cancer
Shanghai Jiao Tong University School of Medicine
Phase 2
120
Shanghai
2023-11-01
Not yet open
Wedge Resection for Ground-glass Opacity-featured Lung Cancer (ECTOP-1020)
NCT06102161Lung Cancer, Wedge Resection, Ground-glass Opacity
Fudan University
Phase 3
286
Shanghai
2023-11
Recruiting
Safety and Efficacy Trial of HG004 for Leber Congenital Amaurosis Related to Rpe65 Gene Mutations (STAR)
NCT05906953Leber Congenital Amaurosis, Inherited Retinal Diseases Caused by RPE65 Mutations
HuidaGene Therapeutics Co., Ltd.
Phase 1/2
20
Shanghai
2023-10-31
Recruiting
The Effect of Continuous Intravenous Infusion of Lidocaine on PPCs and Prognosis in Emergency Surgical Patients With IAI
NCT06304779Postoperative Pulmonary Complications, Intra-abdominal Infection
DrugLidocaine
Shanghai Zhongshan Hospital
Not applicable
428
Shanghai
2023-10-31
Active, closed
Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC
NCT06031558Non-Small Cell Lung Cancer
Shouyao Holdings (Beijing) Co. LTD
Phase 3
120
Shanghai
2023-10-31
Active, closed
A Study of SI-B001+SI-B003ยฑ Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT05949606Non-small Cell Lung Cancer
DrugsSI-B001·SI-B003
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
95
Shanghai
2023-10-30
Recruiting
Circulating Tumor DNA (ctDNA) as a Predictive Biomarker for Immunotherapy in Advanced or Locally Advanced dMMR/MSI-H Colorectal Patients
NCT06098560Colorectal Cancer
Geneplus-Beijing Co. Ltd.
Observational
60
Beijing, Shanghai
2023-10-30
Recruiting
Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC
NCT06081673Head and Neck Squamous Cell Carcinoma
DrugsPenpulimab·Albumin paclitaxel·Cisplatin
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2
72
Shanghai
2023-10-30
Not yet open
Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL
NCT06062641Relapsed or Refractory B-cell Lymphoma
Ruijin Hospital
Phase 2
50
Shanghai
2023-10-30
Recruiting
OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
NCT06182696Relapsed and/or Refractory Multiple Myeloma
DrugOriCAR-017
OriCell Therapeutics Co., Ltd.
Phase 1/2
83
Hangzhou, Beijing, Nanjing, Shanghai, Wuhan
2023-10-26
Recruiting
An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies
NCT06225856Advanced Solid Tumor, Hematological Malignancy
Shanghai Yuyao Biotech Co., Ltd.
Phase 1
96
Shanghai
2023-10-26
Recruiting
Exploration on the Value of MRD Based on ctDNA Detection in Predicting Recurrence of Resected Non-small Cell Lung Cancer
NCT05965024Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Observational
377
Shanghai
2023-10-25
Active, closed
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenstrรถm Macroglobulinemia
NCT05952037Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory
DrugsSonrotoclax·Zanubrutinib
BeOne Medicines
Phase 2
114
Xiamen, Guangzhou, Zhengzhou, Wuhan, Yancheng, Shenyang, Qingdao, Shanghai
2023-10-23
Recruiting
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
NCT06084936Lymphoma
DrugsGlofitamab·Tocilizumab·Bendamustine·Obinutuzumab
Hoffmann-La Roche
Phase 3
182
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanning, Shanghai
2023-10-22
Active, closed
A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares
NCT06013969Generalized Pustular Psoriasis
DrugSpesolimab
LEO Pharma
Phase 4
42
Guangzhou, Shanghai
2023-10-22
Recruiting
A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
NCT06006169Head and Neck Squamous Cell Carcinoma
DrugsSI-B003·Iza-bren
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
186
Shanghai
2023-10-20
Recruiting
Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Malignancies
NCT05991908Acute Myeloid Leukemia, Myelodysplastic Syndromes
DrugFludarabine and Busulfan
Shanghai Jiao Tong University School of Medicine
Phase 3
222
Fuzhou, Xiamen, Nanning, Nanjin, Suzhou, Shanghai, Kunming
2023-10-19
Recruiting
Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (PLOF) for Resectable Locally Advanced Gastric Cancer
NCT06054906Gastric Cancer
DrugSintilimab
Huashan Hospital
Phase 2
50
Shanghai
2023-10-18
Recruiting
A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer
NCT06111274Advanced Pancreatic Cancer
DrugPimicotinib
Abbisko Therapeutics Co, Ltd
Phase 2
82
Shanghai, Chengdu, Haโ€™erbin, Wuhan
2023-10-17
Recruiting
Clinical Trial to Evaluate the Safety and Efficacy of an Implantable Neural Acquisitor & Stimulator System in Patients With Motor Disability
NCT05920174Tetraplegia
Neuracle Medical Technology(Shanghai) Co.,Ltd.
Not applicable
9
Beijing, Shanghai
2023-10-17
By invitation
Identification and Functional Study of Novel Biomarkers for Cardiovascular Diseases
NCT06690684Angiocardiography, Heart Failure, Ischemic Heart Disease, Acute Myocardial Infarction (AMI)
Ya-Wei Xu
Observational
300
Shanghai
2023-10-17
Recruiting
De-escalation Radiation Strategy After NAC in Combination With ICI in LAHNSCC
NCT06572514Locally Advanced Head and Neck Squamous Cell Carcinoma
Ruijin Hospital
Phase 1/2
20
Shanghai
2023-10-17
Recruiting
Efficacy and Safety of Combo-stim Deep Brain Stimulation for Treatment-refractory Mental Disorders
NCT06112067Deep Brain Stimulation
Shanghai Mental Health Center
Not applicable
18
Shanghai
2023-10-16
Recruiting
Preoperative Serum FGF19 in the Prognosis of Biliary Atresia
NCT05848310Biliary Atresia, Prognosis
Children's Hospital of Fudan University
Observational
200
Shanghai
2023-10-15
Recruiting
Cohort of Twin Pregnancy and the Offspring
NCT05727085Twin Pregnancy
Fudan University
Observational
1,000
Shanghai
2023-10-15
Recruiting
DAREONโ„ข-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT05882058Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma
Boehringer Ingelheim
Phase 2
204
Chengdu, Hangzhou, Jinan, Nanchang, Shanghai
2023-10-13
Recruiting
A Clinical Study on the Efficacy of Cognitive Distraction Focus Relaxation Therapy Based on MR
NCT06290011Pain
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Observational
132
Shanghai
2023-10-11
Recruiting
Transbronchial vs Transthoracic Ablation for Early-stage Peripheral Lung Cancer
NCT06052098Stage IA Lung Cancer
Hangzhou Broncus Medical Co., Ltd.
Not applicable
110
Shanghai
2023-10-11
Recruiting
Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis
NCT06451172Bacterial Keratitis, Antibiotic-resistant Bacteria, Infections, Bacterial, Corneal Diseases
Eye & ENT Hospital of Fudan University
Phase EARLY_PHASE1
20
Shanghai
2023-10-11
Active, closed
Acute Health Effects of Low Temperature Exposure
NCT06076629Cardiovascular System, Respiratory System, Cognitive Function
Fudan University
Not applicable
50
Shanghai
2023-10-10
Recruiting
A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction
NCT06082037Lung Transplant Rejection
DrugsAzithromycin·Belumosudil
Sanofi
Phase 3
180
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Shanghai, Wuxi
2023-10-10
Recruiting
CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
NCT06560827HCC
CARsgen Therapeutics Co., Ltd.
Phase 1
30
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guanzhou, Hangzhou, Shanghai
2023-10-08
Recruiting
Clinical Study of Multimodal Ablation Remodeling Immunosensitized PD-1 in the Treatment of Pancreatic Cancer With Liver Metastasis
NCT06307080Pancreatic Cancer
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
12
Shanghai
2023-10-08
By invitation
A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
NCT06044337Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
DrugLitifilimab
Biogen
Phase 3
306
Beijing, Shenzhen, Dongguan, Guangzhou, Changsha, Nanjing, Shanghai, Kunming
2023-10-03
Recruiting
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
NCT05609630Juvenile Idiopathic Arthritis
DrugsUpadacitinib·Tocilizumab
AbbVie
Phase 3
90
Chongqing, Suzhou, Xi'an, Shanghai, Hangzhou
2023-10-02
Recruiting
Development and Validation of the Modified Version of VascuQol Scale in Patients With Lower Extremity Peripheral Arterial Disease.
NCT06223217Peripheral Arterial Disease
RenJi Hospital
Observational
480
Shanghai
2023-10-01
Recruiting
Glycoprotein in Immunotherapy Response and Efficacy Prediction of Lung Cancer
NCT06730503Non Small Cell Lung Cancer
Shanghai Chest Hospital
Observational
250
Shanghai
2023-10-01
Recruiting
LRAMPS Versus LDP in Selected Early-stage Left-sided Pancreatic Cancer
NCT05939063Left-sided Pancreatic Cancer
Fudan University
Not applicable
160
Shanghai
2023-10-01
Recruiting
A Prospective Multicentre Clinical Study of Dynamic Monitoring of Plasma ctDNA Methylation Markers to Predict Recurrence of Colorectal Cancer After Complete Resection of Peritoneal Metastases
NCT06903325Colorectal Cancer, Peritoneal Metastases
Fudan University
Observational
50
Shanghai
2023-10-01
Recruiting
Real-World Study of DLBCL With Different Genetic Subtypes
NCT06026488DLBCL - Diffuse Large B Cell Lymphoma, Lymphoma
Ruijin Hospital
Observational
10,000
Shanghai
2023-10-01
Recruiting
Amplification of Autologous Epidermal Cells to Repair Large Area Deep Wounds
NCT05882110Autologous Epidermal Cell Transplantation
Yicheng Ma
Not applicable
100
Shanghai
2023-10-01
Recruiting
Repeat Intravenous Infusions of B4T2-001 CAR-T Without Lymphodepleting Chemotherapy for Solid Tumors
NCT06072989Advanced Solid Tumor
Shanghai East Hospital
Phase 1
24
Shanghai
2023-10
Recruiting
Tumor Vaccines for Solid Tumors
NCT06102837Glioma, Solid Tumor
DrugTumor vaccine
Huashan Hospital
Observational
340
Shanghai
2023-10
Not yet open
Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis
NCT05860907Breast Cancer Stage IV
DrugHuaier
Fudan University
Phase 4
384
Shijiazhuang, Zhengzhou, Changsha, Nantong, Yangzhou, Shanghai, Hangzhou, Jiaxin
2023-10
Active, closed
A Study of ADRX-0706 in Select Advanced Solid Tumors
NCT06036121Solid Tumors, Triple Negative Breast Cancer (TNBC), Urothelial Cancer, Cervical Cancer
Adcentrx Therapeutics
Phase 1
144
Beijing, Fujian, Guangzhou, Hunan, Jinan, Shanghai, Wuhan
2023-09-26
Recruiting
Chinese Community Sample of Hierarchical Model of Psychopathology
NCT06105970Mental Health Issue, Adverse Childhood Experience
Shanghai Mental Health Center
Observational
4,000
Shanghai
2023-09-26
Recruiting
A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
NCT06147570Nonsmall Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 2
62
Shanghai
2023-09-25
Active, closed
A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma.
NCT05987358Biliary Carcinoma
DrugTQB3454
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
165
Beijing, Lanzhou, Tangshan, Shanghai, Tianjin
2023-09-21
Active, closed
A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD
NCT05972473Neovascular Age-related Macular Degeneration
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3
600
Shanghai
2023-09-21
Recruiting
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
NCT05981703Advanced Solid Tumor, Solid Tumor
DrugTislelizumab
BeOne Medicines
Phase 1
337
Hefei, Harbin, Wuhan, Shenyang, Jining, Yantai, Shanghai, Chengdu
2023-09-21
Recruiting
PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor
NCT05801237Locally Advanced/Metastatic Solid Tumors
Shanghai HyaMab Biotech Co.,Ltd.
Phase 1/2
120
Shanghai
2023-09-21
Recruiting
A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors
NCT05957536HER-2 Positive Advanced Solid Tumors
D3 Bio (Wuxi) Co., Ltd
Phase 1
128
Harbin, Shanghai, Hangzhou
2023-09-19
Recruiting
Recurrent High Grade Glioma Treated by LITT
NCT06161610Recurrent High Grade Glioma
Beijing Tiantan Hospital
Not applicable
135
Beijing, Guangzhou, Zhengzhou, Wuhan, Changchun, Shenyang, Jinan, Shanghai
2023-09-19
Recruiting
Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage โ…ก-โ…ขB EGFR Sensitive Mutant NSCLC
NCT05987826Non-Small Cell Lung Cancer
Shanghai Zhongshan Hospital
Phase 2
40
Shanghai
2023-09-19
Recruiting
Multidisciplinary Diagnosis and Treatment of Polycystic Ovary Syndrome
NCT06047574Polycystic Ovary Syndrome
Shanghai 10th People's Hospital
Observational
3,000
Shanghai
2023-09-18
Recruiting
Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent Beta-thalassemia
NCT05773729ฮฒ-thalassemia
Shanghai BDgene Co., Ltd.
Not applicable
10
Shanghai
2023-09-15
Recruiting
Cryoablation Combined with Tislelizumab Plus Lenvatinib in Previously Treated Solid Tumors (CASTLE-11)
NCT06032845Solid Tumor, Adult
DrugsLenvatinib·Tislelizumab
Fudan University
Phase 2
25
Shanghai
2023-09-13
Active, closed
Efficacy and Safety of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations
NCT07054632Inherited Retinal Dystrophy Associated With RPE65 Mutations
Innostellar Biotherapeutics Co.,Ltd
Phase 3
30
Guangzhou, Chongqing, Shanghai, Tianjin
2023-09-13
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
DrugBelimumab
GlaxoSmithKline
Phase 2/3
300
Beijing, Changchun, Chengdu, Luzhou, Mianyang, Nanjing, Nanning, Shanghai
2023-09-13
Active, closed
Fellow-eye Study (FE) of LX101 in Subjects With Inherited Retinal Dystrophy
NCT06212297Inherited Retinal Dystrophy
Innostellar Biotherapeutics Co.,Ltd
Phase 1/2
9
Shanghai
2023-09-12
By invitation
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
NCT05979441Myositis, Active Idiopathic Inflammatory Myopathy, Dermatomyositis, Polymyositis
DrugEfgartigimod PH20
argenx
Phase 3
240
Guangzhou, Nanjing, Beijing, Chengdu, Shanghai, Shenyang, Zhengzhou
2023-09-12
Recruiting
FreeFlow Percutaneous Atrial Septal Shunt for IPAH
NCT06605794Pulmonary Arterial Hypertension
Shanghai Zhongshan Hospital
Not applicable
30
Shanghai
2023-09-11
Rows per page Showing 2801–2900 of 3827
Previous 27 28 29 30 31 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/shanghai?page=29

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 3,827 of those studies with a site in Shanghai.

How many clinical trials are recruiting in Shanghai?

2,393 of the 3,827 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 737 have not yet opened recruitment, 588 are active but closed to new participants, and 109 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.